- Home
- NMRA vs CGEM Comparison
NMRA vs CGEM Comparison
Compare NMRA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- CGEM
- Stock Information
- Founded
- NMRA 2019
- CGEM 2016
- Country
- NMRA United States
- CGEM United States
- Employees
- NMRA N/A
- CGEM N/A
- Industry
- NMRA
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- CGEM Health Care
- Exchange
- NMRA Nasdaq
- CGEM Nasdaq
- Market Cap
- NMRA 424.4M
- CGEM 437.2M
- IPO Year
- NMRA 2023
- CGEM 2021
- Fundamental
- Price
- NMRA $2.20
- CGEM $13.16
- Analyst Decision
- NMRA Buy
- CGEM Strong Buy
- Analyst Count
- NMRA 8
- CGEM 7
- Target Price
- NMRA $7.57
- CGEM $27.14
- AVG Volume (30 Days)
- NMRA 1.9M
- CGEM 1.1M
- Earning Date
- NMRA 11-06-2025
- CGEM 11-06-2025
- Dividend Yield
- NMRA N/A
- CGEM N/A
- EPS Growth
- NMRA N/A
- CGEM N/A
- EPS
- NMRA N/A
- CGEM N/A
- Revenue
- NMRA N/A
- CGEM N/A
- Revenue This Year
- NMRA N/A
- CGEM N/A
- Revenue Next Year
- NMRA N/A
- CGEM N/A
- P/E Ratio
- NMRA N/A
- CGEM N/A
- Revenue Growth
- NMRA N/A
- CGEM N/A
- 52 Week Low
- NMRA $0.61
- CGEM $5.68
- 52 Week High
- NMRA $11.57
- CGEM $13.78
- Technical
- Relative Strength Index (RSI)
- NMRA 41.50
- CGEM 82.06
- Support Level
- NMRA $2.55
- CGEM $8.52
- Resistance Level
- NMRA $2.78
- CGEM $9.10
- Average True Range (ATR)
- NMRA 0.26
- CGEM 0.91
- MACD
- NMRA -0.09
- CGEM 0.38
- Stochastic Oscillator
- NMRA 10.56
- CGEM 99.92
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.